• Create Account
  • Sign In
  • My account
    Orders Downloads Address Payment methods Account details
  • SUBSCRIBE
  • SEARCH
MY ACCOUNT
  • Create Account
  • Sign In
  • My account
    Orders Downloads Address Payment methods Account details
  • SUBSCRIBE
  • SEARCH
Action Another action Something else here
logo
  • CME
  • JOURNALS
        • Journals
          • The Journal of Clinical Psychiatry
          • JCP Current Issue
          • JCP Weekly
          • JCP Archives
          • The Primary Care Companion for CNS Disorders
          • PCC Current Issue
          • PCC Weekly
          • PCC Archives
  • TOPICS
        • Topics
          • Addiction
          • Anxiety
          • Bipolar Disorder
          • COVID-19
          • Depression (MDD)
          • Eating Disorders
          • Movement Disorders
          • Neurodevelopmental
          • Neurologic and Neurocognitive
          • Obsessive-Compulsive and Related Disorders
          • Personality Disorders
          • Psychopharmacology
          • Schizophrenia and Schizoaffective Disorders
          • Sleep-Wake
          • Tardive Dyskinesia
          • Trauma
          • See all Topics
  • AUTHORS/REVIEWERS
    • Reprints and Permissions
    • Information for Authors (PCC)
    • Submit a PCC Paper
    • Information for Authors (JCP)
    • Submit a JCP Paper
    • Information for Reviewers
  • RESOURCES
    • Media Relations
    • Information for Advertisers
    • CNS Job Market
    • FAQ
Action Another action Something else here

Topics

Anxiety

Anxiety

Showing 421–425 of 425 results

    ARTICLES

    Introduction/Treatment of Panic Disorder: The State of the Art

    Jerrold F. Rosenbaum
    ORIGINAL ARTICLES

    The Infrequency of “Pure Culture” Diagnoses Among the Anxiety Disorders

    Idell M. Goldenberg & more
    ORIGINAL ARTICLES

    The Offensive Subtype of Taijin-Kyofu-Sho in New York City: The Phenomenology and Treatment of a Social Anxiety Disorder

    Susan R. Clarvit and Michael R. Liebowitz
    ORIGINAL ARTICLES

    Fluvoxamine Attenuates Panic Induced by 35% CO2 Challenge

    Henk J. Pols & more
    ORIGINAL ARTICLES

    Paroxetine in Social Phobia

    Catherine Mancini and Michael Van Ameringen
    1 … 34 35 36

MOST POPULAR
CASE REPORT

Sugar Addictive Behavior Resulting From Hypoglycemia Provoked by Insulin Misuse

Here, the authors present a case of a patient with alcohol use disorder who developed an a...

Juliette Salles & more
CASE REPORT

Catatonia as Presenting Manifestation of Behavioral Frontotemporal Dementia: Insight From a PET/MRI Study

In this report, the authors discuss a case of behavioral frontotemporal dementia presentin...

Sara Pompanin & more
CASE REPORT

Delayed Ejaculation in a Man and Premature Orgasm in a Woman: 2 Cases With a Common Suspect

In this case series, the authors describe a case of delayed ejaculation and a case of prem...

Bishurul Hafi & more

© Copyright 2021

Physicians Postgraduate Press, Inc.
Lifelong Learning for Clinicians

  • JCP ISSN: Online 1555-2101, Print 0160-6689
  • PCC ISSN: Online 2155-7780, Print 2155-7772
  • MedFair.com US Patent No. 684794
  • Contact Us
  • Customer Service
  • FAQ
  • About Psychiatrist.com
  • Call for Papers
  • Information for Authors (PCC)
  • Information for Authors (JCP)
  • Reprints and Permissions
  • Media
  • Advertisers
  • CNS Job Market
  • Privacy Policy
  • Unsubscribe from Elerts
  • Terms of Use
Search Articles
Action Another action Something else here
click
Hello Pop
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1 First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2). Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
Related Articles
Table Of Contents